英語ページ

Publications 2012

  1. Habuchi, T., Terachi, T., Mimata, H., Kondo, Y., Kanayama, H., Ichikawa, T., Nutahara, K., Miki, T., Ono, Y., Baba, S., Naito, S. and Matsuda, T. (2012) Evaluation of 2,590 urological laparoscopic surgeries undertaken by urological surgeons accredited by an endoscopic surgical skill qualification system in urological laparoscopy in Japan.Surg. Endosc., 26, 1656-1663.
  2. Tsuchiya N, Narita S, Inoue T, Saito M, Numakura K, Huang M, Hatakeyama S, Satoh S, Saito S, Ohyama C, Arai Y, Ogawa O. and Habuchi T. (2012) Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis. BMC Cancer. 2013 Mar 25;13:150.
  3. Narita, S., Tsuchiya, N., Kumazawa, T., Maita, S., Numakura, K., Obara, T., Tsuruta, H., Saito, M., Inoue, T., Horikawa, Y., Satoh, S., Nanjyo, H.and Habuchi, T. (2012) Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J. Surg. Oncol., 10, 1.
  4. Narita, S., Tsuchiya, N., Yuasa, T., Maita, S., Obara, T., Numakura, K., Tsuruta, H., Saito, M., Inoue, T., Horikawa, Y., Satoh, S.and Habuchi, T. (2012) Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int. J. Clin. Oncol., 17, 204-211.
  5. Inoue, T., Matsuura, K., Yoshimoto, T., Nguyen, L. T., Tsukamoto, Y., Nakada, C., Hijiya, N., Narimatsu, T., Nomura, T., Sato, F., Nagashima, Y., Kashima, K., Hatakeyama, S., Ohyama, C., Numakura, K., Habuchi, T., Nakagawa, M., Seto, M., Mimata, H., and Moriyama, M. (2012) Genomic profiling of renal cell carcinoma in patients with end-stage renal disease. Cancer Sci., 103, 569-576.
  6. Saito, M., Tsuchiya, N., Narita, S., Kumazawa, T., Maita, S., Numakura, K., Obara, T., Tsuruta, H., Inoue, T., Horikawa, Y., Satoh, S.and Habuchi, T. (2012) Comparison of the clinical outcome and systemic inflammatory marker levels between retroperitoneal and transperitoneal laparoscopic donor nephrectomy. J. Endourol., 26, 1038-1043.
  7. Numakura, K., Satoh, S., Tsuchiya, N., Saito, M., Maita, S., Obara, T., Tsuruta, H., Inoue, T., Narita, S., Horikawa, Y., Kagaya, H., Miura, M., and Habuchi, T. (2012) Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival. Transplantation, 94, 145-151.
  8. Maita, S., Yuasa, T., Tsuchiya, N., Mitobe, Y., Narita, S., Horikawa, Y., Hatake, K., Fukui, I., Kimura, S., Maekawa, T.and Habuchi, T. (2012) Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int. J. Cancer, 130, 677-684.
  9. Huang, M., Narita, S., Numakura, K., Tsuruta, H., Saito, M., Inoue, T., Horikawa, Y., Tsuchiya, N.and Habuchi, T. (2012) A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling. Prostate, 72, 1779-1788.
  10. Kumazawa, T., Tsuchiya, N., Inoue, T., Obara, T., Tsuruta, H., Saito, M., Narita, S., Horikawa, Y., Satoh, S.and Habuchi, T. (2012) Association between various indices of obesity and intraoperative factors in laparoscopic donor nephrectomy. J. Laparoendosc. Adv. Surg. Tech. A., 22, 567-571.
  11. Akamatsu, S., Takahashi, A., Takata, R., Kubo, M., Inoue, T., Morizono, T., Tsunoda, T., Kamatani, N., Haiman, C. A., Wan, P., Chen, G. K., Le Marchand, L., Kolonel, L. N., Henderson, B. E., Fujioka, T., Habuchi, T., Nakamura, Y., Ogawa, O., and Nakagawa, H. (2012) Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese. PLoS One, 7, e46454.
  12. Kagaya, H., Miura, M., Niioka, T., Saito, M., Numakura, K., Habuchi, T.and Satoh, S. (2012) Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. Antimicrob. Agents Chemother., 56, 825-829.
  13. Akamatsu, S., Takata, R., Haiman, C. A., Takahashi, A., Inoue, T., Kubo, M., Furihata, M., Kamatani, N., Inazawa, J., Chen, G. K., Le Marchand, L., Kolonel, L. N., Katoh, T., Yamano, Y., Yamakado, M., Takahashi, H., Yamada, H., Egawa, S., Fujioka, T., Henderson, B. E., Habuchi, T., Ogawa, O., Nakamura, Y. and Nakagawa, H. (2012) Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese.Nat. Genet., 44, 426-429.
  14. Mezaki, Y., Morii, M., Yoshikawa, K., Yamaguchi, N., Satoyoshi, K., Miura, M., Imai, K., Hebiguchi, T., Habuchi, T. and Senoo, H. (2012) Elevated expression of transforming growth factor β3 in carbon tetrachloride-treated rat liver and involvement of retinoid signaling. Int. J. Mol. Med., 29, 18-24.
  15. Niioka, T., Satoh, S., Kagaya, H., Numakura, K., Inoue, T., Saito, M., Narita, S., Tsuchiya, N., Habuchi, T.and Miura, M. (2012) Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation, 94, 1013-1019.
  16. Suzuki, Y., Sutoh, M., Hatakeyama, S., Mori, K., Yamamoto, H., Koie, T., Saitoh, H., Yamaya, K., Funyu, T., Habuchi, T., Arai, Y., Fukuda, M., Ohyama, C. and Tsuboi, S. (2012) MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int. J. Oncol., 40, 1831-8.
  17. Yuasa, T., Tsuchiya, N., Urakami, S., Horikawa, Y., Narita, S., Inoue, T., Saito, M., Yamamoto, S., Yonese, J., Fukui, I., Nakano, K., Takahashi, S., Hatake, K.and Habuchi, T. (2012) Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. BJU Int., 109, 1349-1354.

メニューを開く